Leung AM, Pearce EN, Braverman LE, Stagnaro-Green A
Novo Nordisk recently received FDA approval to bring its oral semaglutide formulation, Rybelsus, under the Ozempic brand aligning oral and injectable semaglutide for type 2 diabetes under a single, highly recognized name
In the present study, we found that the fork head box O (FOXO) transcription factor FOXO4 was specially expressed in human Leydig cells and that its translocation to the nucleus in the elderly was related to decreased testosterone synthesis
A study conducted on a non-Caucasian Algerian population was the first to demonstrate the genotypic association between an intronic variant in the IP6K3 gene and a reduced risk for HT
December 17th, 2024: Danish studies link Ozempic to doubled risk of rare vision loss condition Novo Nordisks Ozempic is facing scrutiny after two Danish studies found a potential link between the diabetes drug and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing vision loss due to reduced blood flow to the optic nerve
